Aardvark Therapeutics, Inc. (AARD) Stock Forecast
AARD analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 3.82 / 5 from 11 analysts
- Price target
- $11.11 average of analyst targets
- Upside to target
- +193.9% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.74
- 52-week range
- $3.48 – $15.82
AARD analyst ratings
11 analystsNumber of analysts at each rating.
AARD price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
AARD earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.75 | −$1.07 | −$0.59 | −$0.75 | +0.3% | 8 |
| Current fiscal year (2026) | −$3.17 | −$3.82 | −$2.58 | −$2.93 | −8.1% | 8 |
| Next fiscal year (2027) | −$2.38 | −$3.48 | −$1.77 | −$3.17 | +24.8% | 8 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
AARD revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 8 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 8 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 8 |
AARD EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
AARD EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.87 | −$0.88 | −$0.77 | −$0.77 | −$0.75 | −14.0% | 4 up · 3 down |
| Current fiscal year (2026) | −$3.65 | −$3.67 | −$3.17 | −$3.17 | −$3.17 | −13.2% | 6 up · 1 down |
| Next fiscal year (2027) | −$3.24 | −$3.10 | −$2.78 | −$2.78 | −$2.38 | −26.4% | 4 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
AARD earnings surprises
Reported EPS vs the consensus estimate for the last 7 quarters; AARD beat in 3 of 7.
What analysts expect from AARD
11 analysts cover Aardvark Therapeutics; their consensus rating is buy (3.82 on a 1–5 scale, where 5 is a strong buy). The average price target is $11.11, 193.9% above the latest close of $3.78. Analysts expect earnings of −$3.17 per share for 2026, −8.1% from a year earlier. For 2027 the average estimate is −$2.38 per share. Aardvark Therapeutics beat the EPS estimate in 3 of the last 7 quarters.
Related: AARD income statement, AARD key metrics, AARD chart. See the AARD stock overview for the latest quote and news.
AARD forecast FAQ
What is Aardvark Therapeutics's price target?
The average analyst price target for Aardvark Therapeutics is $11.11, 193.9% above the latest close of $3.78.
Is Aardvark Therapeutics a buy, hold or sell?
Of 11 analysts covering Aardvark Therapeutics, 6 rate it a strong buy, 0 a buy, 3 a hold, 1 a sell and 1 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Aardvark Therapeutics's EPS forecast?
Analysts forecast −$3.17 per share for 2026 (range −$3.82 to −$2.58); for 2027 the estimate is −$2.38.
When does Aardvark Therapeutics report earnings?
Aardvark Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 after the market closes; the EPS estimate is $-0.74.
Does Aardvark Therapeutics usually beat earnings estimates?
Aardvark Therapeutics reported EPS at or above the analyst estimate in 3 of the last 7 quarters.